Finance

Lists
FRX:TSE
Fennec Pharmaceuticals Inc
CAD 15,43
0,00%
(0,00) 1D
28 Sep., 10:11:44 GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for FRX...
Mkt. cap
544,01 m
Avg. vol.
484,00
Volume
0,00
52-wk high
CAD 17,64
52-wk low
CAD 7,59
EPS
-CAD 0,17
Beta
0,85
Shares outstanding
35,07 m
No. of employees
35
Mkt. cap
544,01 m
Avg. vol.
484,00
Volume
0,00
52-wk high
CAD 17,64
52-wk low
CAD 7,59
EPS
-CAD 0,17
Beta
0,85
Shares outstanding
35,07 m
No. of employees
35
About Fennec Pharmaceuticals Inc
CEO-
Employees35
Founded1996
HeadquartersDurham, Noord-Carolina, Verenigde State van Amerika
Sector-
Last report
11 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
- / USD 0,02
Revenue / Est. (USD)
17,87 m / 16,12 m
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
12,46 m
13,78 m
15,11 m
17,87 m
Cost of goods sold
660,00 k
1,76 m
570,00 k
721,00 k
Cost of revenue
660,00 k
1,76 m
570,00 k
721,00 k
Research and development expenses
29,00 k
20,00 k
49,00 k
118,00 k
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,96 m
14,55 m
14,61 m
15,30 m
Operating expense
11,99 m
14,57 m
14,66 m
15,42 m
Total operating expenses
12,65 m
16,33 m
15,23 m
16,14 m
Operating income
-189,00 k
-2,55 m
-119,00 k
1,74 m
Other non operating income
-
-
-
-
EBT including unusual items
-638,00 k
-4,68 m
201,00 k
2,02 m
EBT excluding unusual items
-638,00 k
-2,66 m
201,00 k
2,02 m
Income tax expense
-
106,00 k
-
42,00 k
Effective tax rate
-
-2,26%
-
2,08%
Other operating expenses
-
-
-
-
Net income
-638,00 k
-4,79 m
201,00 k
1,97 m
Net profit margin
-5,12%
-34,75%
1,33%
11,04%
Earnings per share
-0,02
-0,10
-
-
Interest and investment income
152,00 k
228,00 k
339,00 k
287,00 k
Interest expense
-598,00 k
-334,00 k
-7,00 k
-3,00 k
Net interest expenses
-446,00 k
-106,00 k
332,00 k
284,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-163,00 k
-2,53 m
-93,00 k
1,76 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme